CN Patent

CN111171009B — 恩曲替尼晶型及其制备方法

Assigned to Arizest Shanghai Pharmatech Co ltd · Expires 2022-07-12 · 4y expired

What this patent protects

本发明提供了恩曲替尼晶型及其制备方法。具体地，本发明提供了如式I所示的化合物的晶型，所述的晶型为晶型AZT‑A、晶型AZT‑B或晶型AZT‑E。本发明的晶型相比现有的恩曲替尼晶型具有更优异的溶解度、稳定性好、静电作用更新，且制备工艺简单、可操作性强、产率高、质量稳定，生产周期短，易于实现规模化生产。

USPTO Abstract

本发明提供了恩曲替尼晶型及其制备方法。具体地，本发明提供了如式I所示的化合物的晶型，所述的晶型为晶型AZT‑A、晶型AZT‑B或晶型AZT‑E。本发明的晶型相比现有的恩曲替尼晶型具有更优异的溶解度、稳定性好、静电作用更新，且制备工艺简单、可操作性强、产率高、质量稳定，生产周期短，易于实现规模化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN111171009B
Jurisdiction
CN
Classification
—
Expires
2022-07-12
Drug substance claim
No
Drug product claim
No
Assignee
Arizest Shanghai Pharmatech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.